{
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant.",
        "Label": "Entailment"
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "Only 2 patients in the primary trial did not have Recurrence-free Survival",
        "Label": "Entailment"
    },
    "b03bae0b-6811-4c4d-a265-98c0f4ae7f1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "patients who have received gabapentin or herceptin treatment in the past year are not eligible for the secondary clinical trial but can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8127d46a-3a48-4173-8d00-75e949755a74"
        ]
    },
    "1b2048ba-33c8-43d1-8d8f-bca70ca8d80c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "the drug dosage for the primary clinical trial participants is lower in comparison to that of the secondary clinical trial participants.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5fcf6210-c07a-4b8e-9944-c2f0714e4d69"
        ]
    },
    "f398c658-74cb-4d2b-894c-d785e4dde994": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the primary clinical trial and secondary clinical trial utilize different metrics for assessing outcomes.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a06166e6-12c9-49ba-ad3a-7fcfb5234174"
        ]
    },
    "d4b54b4a-d675-4d59-b489-2c1a025b2b4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients with a clinically speculated diagnosis of an inoperable non-small cell lung cancer or small cell lung cancer are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0"
        ]
    },
    "ad00f90a-b69d-4df4-a9f8-d495ac080b38": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "in comparison to patients on aprepitant in the primary clinical trial, those given the placebo intervention were two times more likely to undergo emesis.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "26145056-fdfd-4f2d-909e-be84fc53ede8"
        ]
    },
    "7308389a-7cde-4cf2-8f68-cefff152645c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "there were no occurrences of urinary tract infections among the participants of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "228308ea-2483-4311-a975-ca974ff797c6"
        ]
    },
    "d88cc7fc-34dc-4e86-a3a0-50192a316624": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "the secondary clinical trial allows the participation of patients diagnosed with malignant ductal carcinoma in situ and uncontrolled high blood pressure, whereas such patients are excluded from the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55"
        ]
    },
    "36eb6a9f-5a3a-4f8f-b242-e669aeaa3547": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "participation in the primary clinical trial is not allowed for patients with visible tumors in both breasts",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a0d99371-52e5-4d30-81d5-ad65feba2e4e"
        ]
    },
    "b9e11a69-3cd1-4669-93ae-b644cbd40e71": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial accepts an unlimited number of patients with non-metastatic pancreatic cancer, disregarding presence of kras or braf mutations.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e63ac45b-c34b-4007-820a-30202893fc6f"
        ]
    },
    "57eb42a8-0c1b-4358-b024-0579811b3db3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "interphalangeal joint 5 is a ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand or foot. the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b"
        ]
    },
    "885733b0-a998-4f2c-b131-e58b2008a8a2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "the primary clinical trial is designed for patients who exhibit optimal levels of vitamin d, but such patients may be disqualified from the secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "feca7444-9108-45e9-b722-4f0a207376c7"
        ]
    },
    "b8f0039d-f476-4aa1-a522-751d93e45147": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "results are available for the cohort on lbh589 and lapatinib in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c08aa0d8-5505-438c-b53a-934bd2ee570d"
        ]
    },
    "c6aa83b0-88fb-475a-8b38-e330d2bdf332": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "partial or complete response is a partial or complete response to treatment. the primary trial and the secondary trial adminster their interventions orally.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4c926c31-8786-47b0-a032-1d59f759bca5"
        ]
    },
    "b590614e-03b9-4e7b-91e9-940058316465": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "patients diagnosed with 2-3 cerebral metastases are ineligible for the secondary clinical trial, but they may qualify for the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b685be77-9c55-4948-99cc-2a249739a233"
        ]
    },
    "4a73eb98-e69d-4116-bbed-7e1b6458aa61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 0.12 grams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "292d0dd3-1b9c-4291-b367-0cc1666178db"
        ]
    },
    "eaf2bb85-799b-47e9-af79-4fc7a54f0fcd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "the primary clinical trial administers a dosage of enzalutamide to cohort 2 that is double the corresponding dosage for cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "42c38d71-6a83-4967-ad81-ec38c6b5aafd"
        ]
    },
    "1692ad17-057d-4d84-bc1b-f9fa773288b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "the procedure in the primary clinical trial's first cohort involves an intraosseous injection of fluciclatide, contrastingly, the first cohort in the secondary clinical trial is given an intravenous standard dose of chloroquine.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8180d5e0-b284-45fe-a390-0c3a54dc663f"
        ]
    },
    "f3918549-5e15-44e3-b35b-f7f361845792": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "in the primary clinical trial, all observed adverse events were attributed to members of both cohorts, not exclusively those in cohort 1",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6e1489a6-3a42-4b52-b690-fb1dd8892749"
        ]
    }}